Genentech’s Divarasib Shows Superiority in Head-to-Head Phase III Trial Against Approved KRAS G12C Inhibitors in Non-Small Cell Lung Cancer
Phase 3positivedivarasibPositive
AI Analysis
Summary
Genentech announced positive Phase III results from the Krascendo 1 study showing divarasib demonstrated superiority compared to approved KRAS G12C inhibitors in patients with non-small cell lung cancer. This next-generation KRAS G12C inhibitor data represents a significant competitive advancement in the KRAS-targeted therapy space.
Clinical Trial Data
Phase
Phase III
Primary Endpoint
Met
Outcome Details
Divarasib showed superiority in head-to-head comparison against approved KRAS G12C inhibitors in Phase III Krascendo 1 study
Importance:8/10
Sentiment:
0.85
KRAS G12C inhibitoroncologylung cancerPhase 3 datahead-to-head comparison
Related Companies
Read the original article
Published by Drugs.com Clinical Trial Results on July 1, 2026 8:07 AM